Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

Monte Rosa Therapeutics President & CEO Markus Warmuth reported open-market sales of a total of 5,466 shares of common stock on June 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, at weighted average prices around the high-$18 to high-$19 range.

Insider Trade Summary 10b5-1

Net Seller: 5,466 shares ($106,253)

Net Sell 2 txns

Insider Warmuth Markus

Role President & CEO

Sold 5,466 shs ($106K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,998	$19.412	$97K
Sale	Common Stock	468	$19.7262	$9K

Holdings After Transaction: Common Stock — 595,006 shares (Direct, null)

Footnotes (1)

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.69 to $19.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold (total): 5,466 shares Shares sold (trade 1): 468 shares Price per share (trade 1): $19.7262/share +4 more

7 metrics

Shares sold (total) 5,466 shares Net common shares sold on June 1, 2026

Shares sold (trade 1) 468 shares Common stock open-market sale at weighted average price

Price per share (trade 1) $19.7262/share Weighted average sale price for 468-share transaction

Shares sold (trade 2) 4,998 shares Common stock open-market sale at weighted average price

Price per share (trade 2) $19.4120/share Weighted average sale price for 4,998-share transaction

Reported price range (trade 1) $18.69–$19.68 Range of prices for the multiple executions in trade 1

Reported price range (trade 2) $19.69–$19.77 Range of prices for the multiple executions in trade 2

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, non-derivative, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

""transaction_type": "non-derivative""

common stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warmuth Markus

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		4,998	D	$19.412(2)	595,006	D
Common Stock	06/01/2026		S(1)		468	D	$19.7262(3)	594,538	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.69 to $19.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Markus Warmuth	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Monte Rosa Therapeutics (GLUE) CEO Markus Warmuth report in this Form 4?

The Form 4 shows CEO Markus Warmuth sold a total of 5,466 Monte Rosa Therapeutics common shares in open-market transactions on June 1, 2026. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025.

How many Monte Rosa Therapeutics (GLUE) shares did the CEO sell and at what prices?

Markus Warmuth sold 5,466 common shares in two transactions: 468 shares at a weighted average price of $19.7262 and 4,998 shares at $19.4120. The footnotes note actual trade prices ranged from $18.69 to $19.77.

Were the GLUE insider share sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. Such plans are pre-arranged trading programs that schedule trades in advance, reducing discretion over trade timing.

What type of transactions are reported in this Monte Rosa Therapeutics Form 4?

The Form 4 reports two open-market sales of common stock, each coded as “S” transactions. Both are classified as non-derivative, direct ownership sales, described as “Sale in open market or private transaction” with weighted average prices disclosed in the transaction table.

Does this GLUE Form 4 filing show any option exercises or derivative transactions?

No. The filing’s transaction records involve only non-derivative common stock sales, and the derivativeSummary section is empty. The transactionSummary also shows zero derivative exercises, gifts, tax withholding transactions, or restructuring-related movements for this reporting period.